Comparison of different approaches to modeling early tumor size dynamics for accurate prediction of survival in non-small cell lung cancer (NSCLC) clinical trials

被引：0
|
作者：
Kosinsky, Yuri [1 ]
Azarov, Ivan [1 ]
Chu, Lulu [2 ]
Helmlinger, Gabriel [2 ]
Peskov, Kirill [1 ]
Aksenov, Sergey [2 ]
机构：
[1] M&S Decis LLC, Moscow, Russia
[2] AstraZeneca, IMED Biotech Unit, Cambridge, England
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-075
引用
收藏
页码：S123 / S123
页数：1
相关论文
共 50 条
  • [1] Joint modeling of longitudinal tumor dynamics and survival in non-small cell lung cancer (NSCLC) patients
    Tong, Xiao
    Dunyak, James
    Zhou, Diansong
    Carlile, David
    Tomkinson, Helen
    Helmlinger, Gabriel
    Al-Huniti, Nidal
    Xu, Hongmei
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [2] Prediction of progression free survival using tumor dynamics in non-small cell lung cancer (NSCLC) patients
    Tong, Xiao
    Dunyak, James
    Zhou, Diansong
    Onishchenko, Dmitry
    Carlile, David J.
    Tomkinson, Helen
    Helmlinger, Gabriel
    Al-Huniti, Nidal
    Xu, Hongmei
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S45 - S45
  • [3] Joint modeling of overall survival (OS) and tumor size for patient-level predictions of survival in non-small cell lung cancer (NSCLC)
    Onishchenko, Dmitry
    Dunyak, James
    Masson, Eric
    Helmlinger, Gabriel
    Peskov, Kirill
    Tomkinson, Helen
    Stanski, Donald
    Al-Huniti, Nidal
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S138 - S138
  • [4] The progress of tumor vaccines clinical trials in non-small cell lung cancer
    Wang, Xiaomu
    Niu, Yunping
    Bian, Fang
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [5] REVIEW OF SURVIVAL MODELING APPROACHES ADOPTED IN NICE TECHNOLOGY APPRAISALS (TAS) IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Pandey, S.
    Singh, B.
    Sharma, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S349 - S349
  • [6] DYNAMIC PREDICTION OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN NON-SMALL CELL LUNG CANCER (NSCLC) USING TUMOR SIZE: A LONGITUDINAL JOINT MODELING APPROACH.
    Al-Huniti, N.
    Onishchenko, D.
    Xu, H.
    Zhou, D.
    Masson, E.
    Helmlinger, G.
    Tomkinson, H.
    Abdallah, K.
    Dunyak, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S55 - S55
  • [7] Novel targeted approaches in non-small cell lung cancer (NSCLC)
    Ardizzoni, A.
    Tiseo, M.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : V91 - V93
  • [8] Effect of primary tumor size in patients with metastatic non-small cell lung cancer (NSCLC).
    Xia, Bing
    Gao, Feng
    Govindan, Ramaswamy
    Morgensztern, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Tumor regression as a continuous variable and survival in advanced non-small cell lung cancer (NSCLC).
    Stewart, David J.
    Lu, Charles
    Saintigny, Pierre
    Goss, Glenwood D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] MOLECULAR INEQUALITY IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) AND IMPLICATIONS FOR CLINICAL TRIALS
    Naidoo, Jarushka
    Noonan, Sinead
    Teo, Min Yuen
    Rho, Young Soo
    Clince, Janet
    Gately, Kathy
    O'Grady, Tony
    Kaye, Elaine
    Calvert, Paula
    Morris, Patrick G.
    O'Brien, Cathal
    O'Byrne, Kenneth
    Breathnach, Oscar S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1208 - S1208
12345